XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.70

-0.8%

Jan 23 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert K. who wrote (10774)	7/13/1999 9:16:00 PM
From: Pseudo Biologist	Read Replies (1) of 17367

I am not sure what you mean by the "50% placebo thing", but the following from the xoma.com FAQ may be relevant: <<Is the pivotal trial placebo-controlled? How many patients will be in the control group? What does "double-blind" mean? (2/99) The meningococcemia Phase III study is double-blinded, randomized and placebo-controlled. Patients are randomly assigned to either receive NEUPREX®, or an inert substance (a "placebo"). Approximately equal numbers of patients will be in each group. Both groups also receive the same standard care including antibiotics, often in an intensive care setting. "Double-blinded" means that neither the treating physician nor the sponsoring company knows which patients receive the drug and which receive placebo until the study is concluded and the blind broken. We will not know which patients received NEUPREX® until after the trial is complete and the data are checked and verified.>>

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next